Beam Therapeutics Share Price Today
(NASDAQ: BEAM)

Name: Beam Therapeutics Share Price Today (NASDAQ: BEAM) - Beam Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Beam Therapeutics share price is $25.9 & ₹2,243.98 as on 1 Feb 2025, 2.30 'hrs' IST

$25.9

▲

-1.38

(-5.06%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Beam Therapeutics share price in Dollar and Rupees. Guide to invest in Beam Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Beam Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Beam Therapeutics share price movements

Today's Low: $25.66
Today's High: $27.79
$25.90
0.95%
Downside
Day's Volatility :7.68%
Upside
6.8%
52 Weeks Low: $20.84
52 Weeks High: $49.50
$25.90
19.54%
Downside
52 Weeks Volatility :57.9%
Upside
47.68%

Beam Therapeutics (BEAM) Returns

Period	Beam Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	11.99%	0.3%	0.0%
6 Months	6.52%	-1.5%	0.0%
1 Year	5.25%	5.0%	0.0%
3 Years	-56.49%	12.3%	-12.8%

Beam Therapeutics (BEAM) Key Statistics

in dollars & INR

Previous Close	$27.28
Open	$27.35
Today's High	$27.79
Today's Low	$25.655
Market Capitalization	$2.1B
Today's Volume	$1.0M
52 Week High	$49.5
52 Week Low	$20.84
Revenue TTM	$349.6M
EBITDA	$-160.8M
Earnings Per Share (EPS)	$-1.58
Profit Margin	-41.07%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-18.29%

How to invest in Beam Therapeutics Stock (BEAM) from India?

It is very easy for Indian residents to invest directly in Beam Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Beam Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Beam Therapeutics or BEAM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Beam Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Beam Therapeutics shares which would translate to 0.033 fractional shares of Beam Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Beam Therapeutics, in just a few clicks!

Returns in Beam Therapeutics (BEAM) for Indian investors in Rupees

The Beam Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Beam Therapeutics investment value today

Current value as on today

₹1,04,342

Returns

₹4,342

(+4.34%)

Returns from Beam Therapeutics Stock

₹77 (-0.08%)

Dollar Returns

₹4,419 (+4.42%)

Indian investors sentiment towards Beam Therapeutics (BEAM)

-32%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Beam Therapeutics Stock from India on INDmoney has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Beam Therapeutics

Farallon Capital Management, L.L.C.
9.91%
Vanguard Group Inc
9.47%
BlackRock Inc
9.36%
ARK Investment Management LLC
7.89%
ARCH VENTURE CORP
5.84%
FMR Inc
5.09%

Analyst Recommendation on Beam Therapeutics

Buy

61%Buy

38%Hold

0%Sell

Based on 21 Wall street analysts offering stock ratings for Beam Therapeutics(by analysts ranked 0 to 5 stars)

Based on 21 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Beam Therapeutics Stock (BEAM)

What analysts predicted

Upside of 84.5%

Target:

$47.79

Current:

$25.90

Insights on Beam Therapeutics Stock (Ticker Symbol: BEAM)

Price Movement
In the last 7 days, BEAM stock has moved up by 5.0%
Increasing Revenue
Revenue is up for the last 3 quarters, 7.41M → 14.26M (in $), with an average increase of 27.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -91.05M → -96.66M (in $), with an average decrease of 6.2% per quarter
BEAM vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.3% return, outperforming this stock by 48.5%
BEAM vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 101.4% return, outperforming this stock by 162.0%
Price to Sales
ForBEAM every $1 of sales, investors are willing to pay $6.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.8 for every $1 of sales.

Beam Therapeutics Technicals Summary

Sell

Neutral

Buy

Beam Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Beam Therapeutics (BEAM) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Beam Therapeutics Inc	10.45%	6.52%	5.25%	-56.49%	-64.91%
Biontech Se	4.84%	54.26%	30.47%	-32.9%	299.34%
Regeneron Pharmaceuticals, Inc.	-4.49%	-36.24%	-27.73%	9.67%	100.25%
Vertex Pharmaceuticals Incorporated	8.04%	-8.07%	3.23%	72.89%	90.19%
Alnylam Pharmaceuticals, Inc.	18.64%	4.59%	60.15%	90.8%	141.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Beam Therapeutics Inc	NA	NA	NA	-4.68	-0.18	-0.09	NA	9.97
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.01	17.01	1.06	45.08	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.16	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Beam Therapeutics Inc	Buy	$2.1B	-64.91%	NA	-41.07%
Biontech Se	Buy	$29.0B	299.34%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.5B	100.25%	17.01	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$113.7B	90.19%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.3B	141.72%	NA	-15.86%

Beam Therapeutics Dividend announcements

Beam Therapeutics Earnings
Beam Therapeutics’s price-to-earnings ratio stands at None
Read More

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Organization	Beam Therapeutics
Employees	472
CEO	Mr. John M. Evans M.B.A.
Industry	Health Technology

Management People of Beam Therapeutics

Name	Title
Mr. John M. Evans M.B.A.	CEO & Director
Dr. Giuseppe Ciaramella Ph.D.	President
Dr. Christine P. Bellon J.D., Ph.D.	Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Amy Simon M.D.	Chief Medical Officer
Dr. Feng Zhang Ph.D.	Co-Founder
Dr. David R. Liu Ph.D.	Co-Founder
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder
Mr. Sravan Kumar Emany	Chief Financial Officer
Dr. Manmohan Singh Ph.D.	Chief Technology Officer
Dr. Gopi Shanker Ph.D.	Chief Scientific Officer

Important FAQs about investing in BEAM Stock from India :

What is Beam Therapeutics share price today?

Beam Therapeutics share price today stands at $25.90, Open: $27.35 ; Previous Close: $27.28 ; High: $27.79 ; Low: $25.66 ; 52 Week High: $49.50 ; 52 Week Low: $20.84.

The stock opens at $27.35, after a previous close of $27.28. The stock reached a daily high of $27.79 and a low of $25.66, with a 52-week high of $49.50 and a 52-week low of $20.84.

Can Indians buy Beam Therapeutics shares?

Yes, Indians can invest in the Beam Therapeutics (BEAM) from India.

With INDmoney, you can buy Beam Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Beam Therapeutics at zero transaction cost.

How can I buy Beam Therapeutics shares from India?

It is very easy to buy Beam Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Beam Therapeutics (BEAM) be purchased?

Yes, you can buy fractional shares of Beam Therapeutics with INDmoney app.

What are the documents required to start investing in Beam Therapeutics stocks?

To start investing in Beam Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.